DUBLIN – (BUSINESS WIRE) – May 7, 2021–
Amid the COVID-19 crisis, the global diabetes injection pens market, valued at $ 7.2 billion in 2020, is projected to reach a revised size of $ 11.3 billion by 2027 and in 2020 – grow with a CAGR of 6.7%. 2027.
Type I diabetes, one of the segments analyzed in the report, is expected to have a CAGR of 6.5% and reach $ 6.2 billion by the end of the analysis period. After an early analysis of the business impact of the pandemic and its triggered economic crisis, growth in the Type II diabetes segment will be adjusted to a revised CAGR of 6.9% for the next 7 year period.
The US market is valued at $ 2 billion, while China is forecast to grow 10.1% CAGR
The U.S. diabetes injection pen market is estimated at $ 2 billion in 2020. China, the second largest economy in the world, is expected to reach a projected market size of $ 2.5 billion by 2027, which translates to a CAGR of 10.1% for the analysis period 2020 to 2027. Other notable geographic markets include Japan and Canada, which forecast growth of 3.7% and 6% respectively over the 2020-2027 period. Within Europe, growth of around 4.3% CAGR is forecast for Germany.
Selected participants (43 recommended in total):
- AstraZeneca PLC
- Becton, Dickinson and Company
- Biocon Ltd.
- Eli Lilly and Company
- Jiangsu Delphi Medical Device Co., Ltd.
- Novo Nordisk A / S.
- Owen Mumford Ltd.
- Wockhardt Ltd.
- Influencer Market Insights
- World market trends
- Effects of Covid-19 and an emerging global recession
2. FOCUS ON SELECTED PLAYERS
3. MARKET TRENDS & DRIVERS
4. PERSPECTIVE OF THE GLOBAL MARKET
- UNITED STATES
- CANADA
- JAPAN
- CHINA
- EUROPE
- FRANCE
- GERMANY
- ITALY
- UNITED KINGDOM
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- AUSTRALIA
- INDIA
- SOUTH KOREA
- REST OF ASIA PACIFIC
- LATIN AMERICA
- ARGENTINA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE EAST
- IRAN
- ISRAEL
- SAUDI ARABIA
- UNITED ARAB EMIRATES
- REST OF THE MIDDLE EAST
- AFRICA
- Profiled companies in total: 43
Laura Wood, Senior Press Manager
For EST office hours, call 1-917-300-0470
For US / CAN Toll Free, call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
KEYWORD OF THE INDUSTRY: DIABETES PHARMACEUTICAL HEALTH MEDICAL ACCESSORIES
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 05/07/2021 11:21 AM / DISC: 05/07/2021 11:21 AM
Copyright Business Wire 2021.
